Wall Street Breakfast 24 hour trading takes another step
Jul 21, 2025
Charles Schwab significantly expands its overnight trading platform, adding over 1,100 securities. Verizon impresses with a strong earnings report and raises its profit guidance. Meanwhile, Sarepta Therapeutics faces challenges with the FDA, complicating its path forward. The discussion shifts to Figma's IPO ambitions and how political pressures are influencing Federal Reserve policies, affecting the market landscape. Overall, a deep dive into key financial movements and their implications.
AI Snips
Chapters
Transcript
Episode notes
Schwab's Overnight Trading Expansion
- Schwab expands overnight trading to over 1,100 securities, mainly ETFs, enabling 24/5 trading for retail clients.
- This move reflects strong client demand and a trend towards 24-hour stock trading in the US market.
Verizon Boosts Profit Guidance
- Verizon raises its full-year profit guidance after a strong Q2 earnings beat.
- The company increased its adjusted earnings per share growth and cash flow forecasts, signaling confidence in future performance.
Sarepta Defies FDA on Gene Therapy
- Sarepta Therapeutics continues to decline after refusing FDA's request to halt shipments of its gene therapy.
- The refusal follows reports linking the treatment to three patient deaths, raising regulatory and market concerns.